We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response.
- Authors
Balevic, Stephen J.; Niu, Jing; Chen, Jianmeng; Green, Dionna; McMahon, Ann; Hornik, Christoph P.; Schanberg, Laura E.; Glaser, Rachel; Gonzalez, Daniel; Burckart, Gilbert J.
- Abstract
To streamline drug development, the United States Food and Drug Administration (FDA) can consider the extrapolation of adult efficacy data to children when the disease and drug effects are sufficiently similar. This study explored whether the relationship between drug exposure and response for selected drugs in systemic lupus erythematosus (SLE) was sufficiently similar to support a consideration of the extrapolation of adult efficacy data to children of ≥5 years of age. An exposure–response analysis of drugs used to treat SLE was conducted using published exposure versus response and efficacy versus time data. Statistical analyses included noncompartmental analysis of a drug's area under the effect curve and direct Imax pharmacodynamic (PD) modeling. Six drugs were included: azathioprine, belimumab, cyclophosphamide, hydroxychloroquine, mycophenolate/mycophenolic acid, and rituximab. For belimumab, the net change in responders at week 52 (the primary end point) was nearly identical between 1 adult trial and the pediatric trial. For mycophenolate, PD modeling suggested no significant differences in exposure and SLE disease activity between adults and children. For azathioprine, cyclophosphamide, hydroxychloroquine, and rituximab the data were not sufficient to quantitatively characterize the exposure–response relationship, but the clinical or pharmacologic response between children and adults was similar overall. Adult SLE data should be leveraged to guide pediatric drug development programs and identify areas with residual uncertainty regarding the effectiveness or safety of a drug in children. The degree to which efficacy extrapolation can reduce clinical trial requirements in pediatric SLE should be individualized for each new drug product, depending in part on the mechanism of action of the drug and the similarity of disease manifestations in children and adults.
- Subjects
DRUG metabolism; DRUG efficacy; RITUXIMAB; AZATHIOPRINE; RHEUMATOLOGY; MYCOPHENOLIC acid; UNITED States. Food &; Drug Administration; TREATMENT effectiveness; CYCLOPHOSPHAMIDE; DOSE-effect relationship in pharmacology; DESCRIPTIVE statistics; SYSTEMIC lupus erythematosus; DRUG development; HYDROXYCHLOROQUINE; RECEIVER operating characteristic curves; BELIMUMAB; PATIENT safety; PHARMACODYNAMICS; EVALUATION; CHILDREN
- Publication
Journal of Clinical Pharmacology, 2023, Vol 63, Issue 1, p105
- ISSN
0091-2700
- Publication type
Article
- DOI
10.1002/jcph.2139